HC Wainwright Lifts Earnings Estimates for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.28) per share for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma's Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.60) EPS and FY2028 earnings at ($1.90) EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03.

A number of other equities analysts have also recently commented on the stock. Maxim Group began coverage on shares of Nuvectis Pharma in a research report on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price objective for the company. Laidlaw began coverage on Nuvectis Pharma in a report on Monday, March 17th. They set a "buy" rating and a $19.00 target price for the company.

Nuvectis Pharma Price Performance

NVCT stock traded down $0.23 during midday trading on Friday, reaching $8.99. 121,913 shares of the company were exchanged, compared to its average volume of 126,703. The business has a 50-day moving average price of $8.99 and a two-hundred day moving average price of $7.21. Nuvectis Pharma has a one year low of $4.44 and a one year high of $11.80. The firm has a market capitalization of $212.48 million, a price-to-earnings ratio of -7.75 and a beta of -0.11.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Austin Wealth Management LLC acquired a new position in Nuvectis Pharma in the first quarter valued at about $393,000. Iridian Asset Management LLC CT acquired a new position in Nuvectis Pharma in the first quarter valued at about $2,481,000. Oppenheimer & Co. Inc. raised its stake in Nuvectis Pharma by 64.0% in the first quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company's stock valued at $401,000 after purchasing an additional 16,000 shares in the last quarter. Baldwin Wealth Partners LLC MA raised its stake in Nuvectis Pharma by 0.7% in the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock valued at $3,502,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma in the first quarter valued at about $102,000. Institutional investors and hedge funds own 96.77% of the company's stock.

Insider Transactions at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri bought 12,444 shares of the company's stock in a transaction dated Tuesday, May 6th. The stock was bought at an average price of $8.59 per share, with a total value of $106,893.96. Following the completion of the acquisition, the insider now owns 2,896,565 shares of the company's stock, valued at $24,881,493.35. This represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 35.78% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.